BIOMARIN PHARMACEUTICAL INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$71.73 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-04-27
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$71.73M, a 386.40% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $139.55M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$430.23M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$39.82M, a 152.72% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$305.46M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$484.05M.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$1.18B, a 700.83% decline from fiscal 2014.
- BIOMARIN PHARMACEUTICAL INC net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $196.33M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2018-03-31 | -$71.73M 10-Q · filed 2018-04-27 | $67.81M derived: sum of 2 quarters · filed 2018-04-27 | -$362.42M derived: sum of 3 quarters · filed 2018-04-27 | -$402.24M derived: sum of 4 quarters · filed 2018-04-27 | |||
| 2017-12-31 | $139.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | -$290.68M derived: sum of 2 quarters · filed 2018-02-26 | -$330.51M derived: sum of 3 quarters · filed 2018-02-26 | -$305.46M 10-K · filed 2018-02-26 | |||
| 2017-09-30 | -$430.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | -$470.05M derived: sum of 2 quarters · filed 2017-10-31 | -$445.00M 10-Q · filed 2017-10-31 | -$754.65M derived: sum of 4 quarters · filed 2018-04-27 | |||
| 2017-06-30 | -$39.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$14.78M 10-Q · filed 2017-08-02 | -$324.43M derived: sum of 3 quarters · filed 2018-04-27 | -$651.36M derived: sum of 4 quarters · filed 2018-04-27 | |||
| 2017-03-31 | $25.05M 10-Q · filed 2018-04-27 | -$284.60M derived: sum of 2 quarters · filed 2018-04-27 | -$611.54M derived: sum of 3 quarters · filed 2018-04-27 | -$536.00M derived: sum of 4 quarters · filed 2018-04-27 | |||
| 2016-12-31 | -$309.65M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | -$636.59M derived: sum of 2 quarters · filed 2018-02-26 | -$561.05M derived: sum of 3 quarters · filed 2018-02-26 | -$484.05M 10-K · filed 2018-02-26 | |||
| 2016-09-30 | -$326.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | -$251.40M derived: sum of 2 quarters · filed 2017-10-31 | -$174.40M 10-Q · filed 2017-10-31 | -$94.85M derived: sum of 4 quarters · filed 2018-02-26 | |||
| 2016-06-30 | $75.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $152.54M 10-Q · filed 2017-08-02 | $232.09M derived: sum of 3 quarters · filed 2018-02-26 | $169.01M derived: sum of 4 quarters · filed 2018-02-26 | |||
| 2016-03-31 | $77.00M 10-Q · filed 2017-05-04 | $156.55M derived: sum of 2 quarters · filed 2018-02-26 | $93.47M derived: sum of 3 quarters · filed 2018-02-26 | -$351.73M derived: sum of 4 quarters · filed 2018-02-26 | |||
| 2015-12-31 | $79.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $16.47M derived: sum of 2 quarters · filed 2018-02-26 | -$428.73M derived: sum of 3 quarters · filed 2018-02-26 | -$1.18B 10-K · filed 2018-02-26 | |||
| 2015-09-30 | -$63.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$508.28M derived: sum of 2 quarters · filed 2016-11-03 | -$1.26B 10-Q · filed 2016-11-03 | -$796.47M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-06-30 | -$445.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$1.20B 10-Q · filed 2016-08-08 | -$733.38M derived: sum of 3 quarters · filed 2017-02-27 | -$920.86M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-03-31 | -$750.87M 10-Q · filed 2016-05-02 | -$288.19M derived: sum of 2 quarters · filed 2017-02-27 | -$475.67M derived: sum of 3 quarters · filed 2017-02-27 | -$516.02M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2014-12-31 | $462.68M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $275.21M derived: sum of 2 quarters · filed 2017-02-27 | $234.85M derived: sum of 3 quarters · filed 2017-02-27 | $196.33M 10-K · filed 2017-02-27 | $194.56M 10-K · filed 2015-03-02 | ||
| 2014-09-30 | -$187.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | -$227.84M derived: sum of 2 quarters · filed 2015-11-02 | -$266.36M 10-Q · filed 2015-11-02 | -$266.69M 10-Q · filed 2014-10-28 | -$572.84M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-06-30 | -$40.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$78.88M 10-Q · filed 2015-08-05 | -$79.46M 10-Q · filed 2014-07-31 | -$385.36M derived: sum of 3 quarters · filed 2016-02-29 | -$382.05M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-03-31 | -$38.52M 10-Q · filed 2015-05-05 | -$345.01M derived: sum of 2 quarters · filed 2016-02-29 | -$341.69M derived: sum of 3 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | -$306.49M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$303.17M derived: sum of 2 quarters · filed 2016-02-29 | -$298.85M 10-K · filed 2016-02-29 | -$298.78M 10-K · filed 2015-03-02 | |||
| 2013-09-30 | $3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $7.63M 10-Q · filed 2014-10-28 | |||||
| 2013-06-30 | $4.32M 10-Q · filed 2014-07-31 | ||||||
| 2012-12-31 | -$195.65M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |